Yousif Capital Management LLC Sells 101 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Yousif Capital Management LLC decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 0.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,624 shares of the biotechnology company’s stock after selling 101 shares during the period. Yousif Capital Management LLC’s holdings in United Therapeutics were worth $4,975,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of UTHR. GAMMA Investing LLC bought a new stake in shares of United Therapeutics in the fourth quarter worth $43,000. C M Bidwell & Associates Ltd. bought a new stake in shares of United Therapeutics in the third quarter worth $91,000. Blue Trust Inc. grew its holdings in shares of United Therapeutics by 10.0% in the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 46 shares during the period. CWM LLC grew its holdings in shares of United Therapeutics by 45.7% in the fourth quarter. CWM LLC now owns 670 shares of the biotechnology company’s stock worth $147,000 after acquiring an additional 210 shares during the period. Finally, Synovus Financial Corp bought a new stake in shares of United Therapeutics in the third quarter worth $203,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $235.95 on Friday. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $11.10 billion, a P/E ratio of 11.89 and a beta of 0.52. United Therapeutics Co. has a 12 month low of $204.44 and a 12 month high of $261.54. The business’s 50-day moving average is $233.36 and its 200 day moving average is $228.79.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping the consensus estimate of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company had revenue of $614.70 million for the quarter, compared to analysts’ expectations of $575.01 million. During the same period in the previous year, the firm posted $2.67 earnings per share. The firm’s revenue for the quarter was up 25.1% on a year-over-year basis. On average, equities research analysts forecast that United Therapeutics Co. will post 23.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

UTHR has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $300.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. Wedbush reiterated an “outperform” rating and set a $308.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. Finally, The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and lifted their target price for the company from $213.00 to $215.00 in a research report on Monday, February 12th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $294.25.

Insiders Place Their Bets

In other United Therapeutics news, Director Nilda Mesa sold 325 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $237.80, for a total transaction of $77,285.00. Following the sale, the director now directly owns 5,373 shares of the company’s stock, valued at $1,277,699.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Martine A. Rothblatt sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total value of $3,548,850.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at $30,756.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Nilda Mesa sold 325 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $237.80, for a total value of $77,285.00. Following the completion of the sale, the director now owns 5,373 shares of the company’s stock, valued at approximately $1,277,699.40. The disclosure for this sale can be found here. Insiders have sold 136,990 shares of company stock valued at $32,239,641 over the last ninety days. 12.50% of the stock is owned by insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.